Pharmacokinetics and Pharmacodynamics Practice Questions

Q: In pseudocholinesterase deficiency, which drug should be used cautiously?

Succinylcholine. ***Succinylcholine*** - **Succinylcholine** is primarily metabolized by **pseudocholinesterase** (also known as butyrylcholinesterase). - In individuals with **pseudocholinesterase deficiency**, the metabolism of succinylcholine is significantly delayed, leading to **prolonged neuromuscular blockade** and extended paralysis. *Barbiturates* - **Barbiturates** are mainly metabolized by the **hepatic cytochrome P450 system** and do not depend on pseudocholinesterase for their breakdown. - Their metabolism would not be significantly affected by pseudocholinesterase deficiency. *Halothane (an inhalational anesthetic)* - **Halothane** is primarily metabolized by the **hepatic cytochrome P450 system** and excreted via the lungs. - Its metabolism is unrelated to **pseudocholinesterase activity**. *Gallamine (a neuromuscular blocker)* - **Gallamine** is a **nondepolarizing neuromuscular blocker** that is primarily eliminated by **renal excretion** as an unchanged drug. - Its metabolism and elimination are independent of **pseudocholinesterase**.

Q: Which calcium channel blocker has the shortest duration of action?

Nimodipine. ***Nimodipine*** - Nimodipine is a **dihydropyridine calcium channel blocker** specifically formulated for cerebral vasodilation and used in conditions like **subarachnoid hemorrhage**. - It has a relatively **short half-life** and rapid onset, making its duration of action shorter compared to other commonly used calcium channel blockers. *Amlodipine* - Amlodipine is known for its **long duration of action** and once-daily dosing due to its slow absorption and high bioavailability. - Its prolonged action is beneficial for conditions like **hypertension and angina**, where sustained vasodilation is desired. *Diltiazem* - Diltiazem's duration of action is **intermediate** compared to other calcium channel blockers, often requiring BID to TID dosing for immediate-release formulations. - It's a **non-dihydropyridine calcium channel blocker** with effects on both vascular smooth muscle and cardiac conduction. *Verapamil* - Verapamil also has an **intermediate duration of action**, similar to diltiazem, with immediate-release forms requiring multiple daily doses. - As a **non-dihydropyridine calcium channel blocker**, it has significant effects on myocardial contractility and AV nodal conduction.

Q: Which second generation antihistaminic does not produce an active metabolite?

Cetirizine. ***Cetirizine*** - Cetirizine is unique among second-generation antihistamines as it is an **active metabolite** of hydroxyzine and **does not undergo further significant metabolism** to an active compound. - This characteristic contributes to its relatively **predictable pharmacokinetics** and reduced potential for drug interactions related to metabolism. *Loratadine* - Loratadine is a **prodrug** that is extensively metabolized in the liver by **CYP3A4 and CYP2D6** to its active metabolite, **desloratadine**. - Desloratadine is responsible for most of the **antihistaminic effects** of loratadine. *Terfenadine* - Terfenadine is a **prodrug** that is extensively metabolized by **CYP3A4** to its active metabolite, **fexofenadine**. - Due to its **cardiotoxicity** (QT prolongation) when its metabolism was inhibited, terfenadine was withdrawn from the market, and fexofenadine was developed as a safer alternative. *None of the options* - This option is incorrect because **cetirizine** does not produce an active metabolite, making it a valid answer for the question.

Q: Which of the following statements about lamotrigine is correct?

Has a half-life of approximately 24 hours.. ***Has a half-life of approximately 24 hours.*** - Lamotrigine's **half-life** is typically around **24 to 33 hours** in adults, which allows for once or twice-daily dosing. - This relatively long half-life is advantageous for maintaining **stable plasma concentrations** and improving patient adherence. *Is the first choice for absence seizures.* - **Ethosuximide** or **valproate** are generally considered first-line treatments for **absence seizures**. - Lamotrigine is not the preferred initial therapy due to its **slower titration** and occasional lack of efficacy in this seizure type. *Is not significantly metabolized in the liver.* - Lamotrigine is **significantly metabolized** in the liver, primarily through **glucuronidation** by the **UGT1A4 enzyme**. - This hepatic metabolism explains many of its **drug interactions**, particularly with other antiepileptic drugs affecting UGT enzymes. *Has decreased efficacy in treating depressive episodes.* - Lamotrigine is known for its **mood-stabilizing properties** and is effective in treating and preventing **depressive episodes**, particularly in **bipolar disorder**. - Its efficacy in depression is a key distinguishing feature, making it a valuable option for patients with comorbid mood disorders.

Q: Mode of excretion of cyclophosphamide is?

Kidney. ***Kidney*** - Cyclophosphamide is a **prodrug** that undergoes metabolism in the liver to its active forms. However, both the parent drug and its active metabolites are primarily **excreted renally**. [1] - Renal excretion means that patients with **renal impairment** may require dose adjustments to prevent drug accumulation and increased toxicity. [3] *Lung* - The lungs are primarily involved in **gas exchange** and the elimination of volatile substances, not non-volatile drugs like cyclophosphamide. - While some drugs can be excreted to a minor extent via the lungs, it is not the primary route for **cyclophosphamide**. *Liver* - The liver is the primary site of **metabolism** for cyclophosphamide, where it is converted into active cytotoxic metabolites. [1], [2] - While metabolites are formed here, the liver is not the main organ for the final **elimination** (excretion) of the drug or its metabolites from the body. *Skin* - The skin's role in drug excretion is generally minimal, mainly involving substances excreted in **sweat**, and is not a significant route for cyclophosphamide. - Excretion via the skin is typically very limited for most drugs and does not play a major role in the elimination of **chemotherapeutic agents** like cyclophosphamide.

Q: Which of the following is a metabolite of hydroxyzine?

Cetirizine. ***Cetirizine*** - **Cetirizine** is the principal active metabolite of **hydroxyzine**, formed through the oxidation of the primary alcohol group of hydroxyzine [2]. - Both hydroxyzine and cetirizine are **H1-receptor antagonists**, but cetirizine is a **second-generation antihistamine** known for being less sedating due to its limited ability to cross the blood-brain barrier [2]. *Fexofenadine* - **Fexofenadine** is an active metabolite of **terfenadine**, not hydroxyzine [2]. - **Fexofenadine** is a second-generation antihistamine used to treat allergies, known for its non-sedating properties [3]. *Terfenadine* - **Terfenadine** is a second-generation antihistamine that was withdrawn from the market due to its cardiotoxicity, particularly the risk of **QT prolongation** and **Torsades de Pointes**. - Its active metabolite is **fexofenadine**, which does not cause similar cardiac issues [2]. *Azelastine* - **Azelastine** is an antihistamine primarily available as a **nasal spray** for the treatment of allergic rhinitis and conjunctivitis [1], [3]. - It is not a metabolite of hydroxyzine but a distinct therapeutic compound.

Q: Which of the following factors influences the duration of action of a drug?

All of the options. ***All of the options*** - **Clearance** and **rate of elimination** are the primary determinants of how long a drug stays in the body at therapeutic levels, thus directly influencing its duration of action. - **Bioavailability** affects the intensity and onset but can influence the perceived duration if subtherapeutic concentrations are achieved. - The interplay of these pharmacokinetic parameters ultimately determines the drug's therapeutic window and frequency of dosing. *Clearance* - **Clearance** is the rate at which the active drug is removed from the body, primarily by the kidneys and liver. - A higher clearance generally leads to a shorter elimination half-life and a **shorter duration of action**, as the drug is removed more quickly from the systemic circulation. *Rate of elimination* - The **rate of elimination** directly dictates how quickly the concentration of a drug in the body decreases over time. - A faster elimination rate (shorter half-life) means the drug's effects will wear off sooner, resulting in a **shorter duration of action**. - This is quantified by the elimination rate constant (Kel) and half-life (t½). *Bioavailability* - **Bioavailability** refers to the fraction of an administered dose of unchanged drug that reaches the systemic circulation. - While bioavailability primarily affects the **peak concentration (Cmax)** and **intensity** of drug effect, it can indirectly influence duration. - If bioavailability is very low, therapeutic concentrations may not be sustained long enough, effectively shortening the **clinically relevant duration of action**. - However, two drugs with identical elimination rates but different bioavailabilities will have the same elimination half-life and similar duration at therapeutic doses.

Q: Which route of administration undergoes the maximum first pass metabolism?

Oral. ***Oral*** - Drugs administered orally are absorbed from the **gastrointestinal tract** and transported via the **portal vein** directly to the liver, where they undergo significant **first-pass metabolism** before reaching systemic circulation. - This hepatic metabolism can drastically reduce the **bioavailability** of the drug, requiring higher doses or alternative administration routes. *Intra-arterial* - This route delivers drugs directly into an **artery** supplying a target tissue or organ, largely bypassing systemic circulation and initial hepatic metabolism. - It is used for localized effects, such as **chemotherapy** for specific tumors, minimizing systemic exposure. *Rectal* - While a portion of rectally administered drugs may bypass the portal circulation by entering the **inferior and middle rectal veins**, a significant amount can still be absorbed into the superior rectal vein, which drains into the portal system. - This means rectal administration offers only **partial avoidance** of first-pass metabolism, making it less complete than IV or intra-arterial routes for bypassing the liver altogether. *Intravenous* - Drugs administered intravenously are delivered directly into the **systemic circulation**, completely bypassing the gastrointestinal tract and the liver's first-pass metabolism. - This route ensures **100% bioavailability** and rapid onset of action, as the drug immediately reaches its target.

Q: Which of the following drugs is known to have low first pass metabolism?

Theophylline. ***Theophylline*** - **Theophylline** exhibits **low first-pass metabolism**, meaning a significant portion of the orally administered drug reaches systemic circulation unchanged. - This characteristic contributes to its relatively **high bioavailability** when given orally. *Lidocaine* - **Lidocaine** undergoes extensive **first-pass metabolism** in the liver, leading to very low oral bioavailability. - Due to this, it is typically administered **parenterally** (e.g., intravenously or topically) to achieve therapeutic concentrations. *Propranolol* - **Propranolol** is known for its significant **first-pass metabolism**, which results in a much lower bioavailability after oral administration compared to intravenous. - This extensive metabolism necessitates higher oral doses to achieve the same therapeutic effect as parenteral administration. *Morphine* - **Morphine** also undergoes substantial **first-pass metabolism** in the liver, where it is primarily glucuronidated. - This leads to a lower oral bioavailability compared to other routes of administration and contributes to a higher oral dose requirement.

Q: What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?

Zero order kinetics. ***Zero order kinetics*** - This mechanism occurs when the **metabolic enzymes become saturated at high drug concentrations**, leading to a constant amount (not a constant percentage) of drug being eliminated per unit time. - Alcohol, aspirin, and phenytoin are examples of drugs that exhibit **saturable metabolism**, transitioning from first-order to zero-order kinetics at higher doses. *First pass kinetics* - This describes the **metabolism of a drug by the liver or gut wall enzymes before it reaches systemic circulation** after oral administration. - While relevant to the oral bioavailability of these drugs, it does not describe the specific mechanism of elimination at high doses. *First order kinetics* - In this mechanism, a **constant fraction or percentage of the drug is eliminated per unit of time**, meaning the rate of elimination is directly proportional to the drug concentration. - Most drugs follow first-order kinetics at therapeutic doses because metabolizing enzymes are not saturated. *Second order kinetics* - This is a **less common pharmacokinetic model** where the rate of elimination is proportional to the square of the drug concentration or involves two reactants. - It does not typically describe the common elimination patterns of most drugs, including alcohol, aspirin, and phenytoin.

Question 1

In pseudocholinesterase deficiency, which drug should be used cautiously?

Accepted Answer

Succinylcholine

Answer

Barbiturates

Answer

Gallamine

Answer

Halothane

Question 2

Which calcium channel blocker has the shortest duration of action?

Accepted Answer

Nimodipine

Answer

Diltiazem

Answer

Amlodipine

Answer

Verapamil

Question 3

Which second generation antihistaminic does not produce an active metabolite?

Accepted Answer

Cetirizine

Answer

Loratadine

Answer

Terfenadine

Answer

None of the options

Question 4

Which of the following statements about lamotrigine is correct?

Accepted Answer

Has a half-life of approximately 24 hours.

Answer

Is the first choice for absence seizures.

Answer

Is not significantly metabolized in the liver.

Answer

Has decreased efficacy in treating depressive episodes.

Question 5

Mode of excretion of cyclophosphamide is?

Accepted Answer

Kidney

Answer

Lung

Answer

Liver

Answer

Skin

Question 6

Which of the following is a metabolite of hydroxyzine?

Accepted Answer

Cetirizine

Answer

Fexofenadine

Answer

Terfenadine

Answer

Azelastine

Question 7

Which of the following factors influences the duration of action of a drug?

Accepted Answer

All of the options

Answer

Bioavailability

Answer

Clearance

Answer

Rate of elimination

Question 8

Which route of administration undergoes the maximum first pass metabolism?

Accepted Answer

Oral

Answer

Intra-arterial

Answer

Rectal

Answer

Intravenous

Question 9

Which of the following drugs is known to have low first pass metabolism?

Accepted Answer

Theophylline

Answer

Lidocaine

Answer

Propranolol

Answer

Morphine

Question 10

What is the mechanism of metabolism for alcohol, aspirin, and phenytoin at high doses?

Accepted Answer

Zero order kinetics

Answer

First pass kinetics

Answer

First order kinetics

Answer

Second order kinetics

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?